Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

or the three months to September 30, 2011 (2010: $0.4 million) and $1.4 million for the nine months to September 30, 2011 (2010: $1.3 million). R&D costs include intangible assets impairment charges of $16.0 million for the three months and nine months to September 30, 2011 (2010: $nil). SG&A costs include amortization and impairment charges of intangible assets relating to intellectual property rights acquired of $46.4 million for the three months to September 30, 2011 (2010: $73.9 million) and $119.1 million for the nine months to September 30, 2011 (2010: $142.3 million).

Unaudited US GAAP results for the three months and nine months to September 30, 2011
Consolidated Statements of Income (continued)

3 months to 3 months to 9 months to 9 months to September September September September 30, 30, 30, 30, 2011 2010 2011 2010 Earnings per ordinary share - basic 35.0c 17.6c 110.6c 77.4c Earnings per ADS - basic 105.0c 52.8c 331.8c 232.2c Earnings per ordinary share - diluted 33.9c 17.3c 106.7c 76.0c Earnings per ADS - diluted 101.7c 51.9c 320.1c 228.0c Weighted average number of shares: Millions Millions Millions Millions Basic 551.3 547.0 551.2 546.1 Diluted 593.8 556.7 595.0 589.7

Unaudited US GAAP results for the three months and nine months to September 30, 2011
Consolidated Statements of Cash Flows

3 months to 9 months to September 30, September 30, 2011 2010 2011 2010 $M $M $M $M CASH FLOWS FROM OPERATING ACTIVITIES: Net income 192.9 96.3 609.7 422.7 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 80.0 60.0 212.3 189.2 Share based compensation 19.8 17.5 54.7 44.2 Impairment of intangible assets 16.0 42.7 16.0 42.7 Gain on sale of non-current investments (23.5) - (23.5) (11.1) Loss/(gain) on sale of product rights 0.3 - 3.8 (4.1) Other 11.7 (5.7) 5.9 5.2 Movement in deferred taxes (30.9) (10.0) (13.2) 48.7 Equi
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 Working in collaboration with ... London , Richmond Pharmacology is the first ... 3 study for an investigational RNAi therapeutic being developed for ... the nerves and heart. Read press release ... Based at St Georges University of London ...
(Date:3/27/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a biopharmaceutical ... innovative therapeutics addressing cancer and other unmet medical needs ... China , today reported financial results ... 2014.  The Company reported a net ... the three months ended December 31, 2014.  This compares ...
(Date:3/26/2015)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... solutions for the detection of foodborne pathogens, today ... and full year ended December 31, 2014. ... quarter ended December 31, 2014 was $1.4 million ... 2013 and $1.5 million for the third quarter ...
(Date:3/26/2015)... TORONTO , March 26, 2015 /PRNewswire/ - SQI ... SQIDF) announced that after dealing with certain matters, including ... of shareholders held on March 26, 2015 (the "Meeting") ... until April 8, 2015 at 11:00 a.m. ( ... Meeting has been changed from that previous disclosed. The ...
Breaking Biology Technology:CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7SQI Diagnostics Inc. Announces Adjournment of Meeting 2
... NEW BRUNSWICK, N.J., Dec. 5 Senesco Technologies, Inc. ... today that its Development and License Agreement with the ... mutual agreement because of Harris Moran,s recently announced corporate ... Harris Moran has reported that its parent company, Limagrain, ...
... BioCryst Pharmaceuticals (Nasdaq: BCRX ) announced today ... and BCX-4208, and clinical data on BCX-4208 at the 50th ... held in San Francisco, CA from December 6-9, 2008. ... inhibitors. , , The schedule ...
... YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, ... and commercializes differentiated products for patients worldwide, ... licensee of nimotuzumab from YM,s subsidiary, CIMYM ... the European Medicines Agency (EMEA) for marketing ...
Cached Biology Technology:Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 2Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 3BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition 2BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition 3YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE 2YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE 3
(Date:3/11/2015)... 11, 2015 Research and Markets ( ... "Access Control Market by Product, Application & By Geography ... to their offering. , This report predicts ... $10.4 billion by 2020, with an estimated CAGR of ... the products types such as contact cards & readers, ...
(Date:3/10/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce ... been named the "Number One Best Tech Gift ... Modern ( http://www.rethinkmodern.com/ ) is a web magazine focused ... that have a unique function or design.  ...
(Date:3/2/2015)... 2015  Businesses have a new option for ... Rankins Enterprises has announced the launch of a ... for businesses to protect their customers, personal data, ... Beconux is a biometric transaction processing system ... to an ATM machine, the new system fuses ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Personal Data Protection Company Launches New Product 2
... of California, Berkeley, virologist and an assistant professor in the ... M. Keck Foundation grant, an award given to innovative young ... which totals up to $1 million over five years, will ... herpesvirus as a tool to study the inner workings of ...
... WORCESTER, Mass.In recent years, a class of small molecules known ... in regulating gene products in most animal and plant species. ... development of alcohol tolerance, a hallmark of alcohol abuse and ... and Alcoholism (NIAAA) report the findings in the July 31 ...
... death but now a study of brain tissue collected during ... and suicide. The international research group, led by Dr. ... of Western Ontario and Dr. Hymie Anisman of the Neuroscience ... that proteins that modify DNA directly are more highly expressed ...
Cached Biology News:UC Berkeley virologist named Keck Distinguished Young Scholar 2MicroRNA implicated as molecular factor in alcohol tolerance 2Study identifies changes to DNA in major depression and suicide 2
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
This Universal 24" X 18" (61 X 45.7cm.) shaker platforms will accept any Thermo Forma shaker flask clip....
Disposable tips with floating filter (US Patent 6,702,990) for PDM1.5 OneTouch Plus spotpicker, 10 racks of 96, DNAse and RNAse free...
Biology Products: